211 related articles for article (PubMed ID: 11595726)
61. A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor.
Plath T; Detjen K; Welzel M; von Marschall Z; Murphy D; Schirner M; Wiedenmann B; Rosewicz S
J Cell Biol; 2000 Sep; 150(6):1467-78. PubMed ID: 10995450
[TBL] [Abstract][Full Text] [Related]
62. High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma.
Jonsson A; Tuominen R; Grafström E; Hansson J; Egyhazi S
J Invest Dermatol; 2010 Dec; 130(12):2809-17. PubMed ID: 20703244
[TBL] [Abstract][Full Text] [Related]
63. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
64. The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired.
Becker TM; Ayub AL; Kefford RF; Mann GJ; Rizos H
Int J Cancer; 2005 Nov; 117(4):569-73. PubMed ID: 15945100
[TBL] [Abstract][Full Text] [Related]
65. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.
FitzGerald MG; Harkin DP; Silva-Arrieta S; MacDonald DJ; Lucchina LC; Unsal H; O'Neill E; Koh J; Finkelstein DM; Isselbacher KJ; Sober AJ; Haber DA
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8541-5. PubMed ID: 8710906
[TBL] [Abstract][Full Text] [Related]
66. Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells.
Rotolo S; Diotti R; Gordon RE; Qiao RF; Yao Z; Phelps RG; Dong J
Int J Cancer; 2005 May; 115(1):164-9. PubMed ID: 15657897
[TBL] [Abstract][Full Text] [Related]
67. eMelanoBase: an online locus-specific variant database for familial melanoma.
Fung DC; Holland EA; Becker TM; Hayward NK; Bressac-de Paillerets B; Mann GJ;
Hum Mutat; 2003 Jan; 21(1):2-7. PubMed ID: 12497626
[TBL] [Abstract][Full Text] [Related]
68. Overexpression of mutant ras in human melanoma increases invasiveness, proliferation and anchorage-independent growth in vitro and induces tumour formation and cachexia in vivo.
Fujita M; Norris DA; Yagi H; Walsh P; Morelli JG; Weston WL; Terada N; Bennion SD; Robinson W; Lemon M; Maxwell IH; Yohn JJ
Melanoma Res; 1999 Jun; 9(3):279-91. PubMed ID: 10465584
[TBL] [Abstract][Full Text] [Related]
69. Expression and characterization of Syrian golden hamster p16, a homologue of human tumor suppressor p16 INK4A.
Li J; Qin D; Knobloch TJ; Tsai MD; Weghorst CM; Melvin WS; Muscarella P
Biochem Biophys Res Commun; 2003 May; 304(2):241-7. PubMed ID: 12711305
[TBL] [Abstract][Full Text] [Related]
70. Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer.
Zhao R; Choi BY; Lee MH; Bode AM; Dong Z
EBioMedicine; 2016 Jun; 8():30-39. PubMed ID: 27428416
[TBL] [Abstract][Full Text] [Related]
71. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.
Soufir N; Avril MF; Chompret A; Demenais F; Bombled J; Spatz A; Stoppa-Lyonnet D; Bénard J; Bressac-de Paillerets B
Hum Mol Genet; 1998 Feb; 7(2):209-16. PubMed ID: 9425228
[TBL] [Abstract][Full Text] [Related]
72. Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells.
Rizos H; Darmanian AP; Indsto JO; Shannon JA; Kefford RF; Mann GJ
Melanoma Res; 1999 Feb; 9(1):10-9. PubMed ID: 10338330
[TBL] [Abstract][Full Text] [Related]
73. Dissection of CDK4-binding and transactivation activities of p34(SEI-1) and comparison between functions of p34(SEI-1) and p16(INK4A).
Li J; Muscarella P; Joo SH; Knobloch TJ; Melvin WS; Weghorst CM; Tsai MD
Biochemistry; 2005 Oct; 44(40):13246-56. PubMed ID: 16201750
[TBL] [Abstract][Full Text] [Related]
74. Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.
Jenkins NC; Jung J; Liu T; Wilde M; Holmen SL; Grossman D
J Invest Dermatol; 2013 Apr; 133(4):1043-51. PubMed ID: 23190892
[TBL] [Abstract][Full Text] [Related]
75. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
[TBL] [Abstract][Full Text] [Related]
76. Phosphorylation of p16INK4A correlates with Cdk4 association.
Gump J; Stokoe D; McCormick F
J Biol Chem; 2003 Feb; 278(9):6619-22. PubMed ID: 12529334
[TBL] [Abstract][Full Text] [Related]
77. Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16.
Mahajan A; Guo Y; Yuan C; Weghorst CM; Tsai MD; Li J
J Mol Biol; 2007 Nov; 373(4):990-1005. PubMed ID: 17881001
[TBL] [Abstract][Full Text] [Related]
78. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
Horn IP; Marks DL; Koenig AN; Hogenson TL; Almada LL; Goldstein LE; Romecin Duran PA; Vera R; Vrabel AM; Cui G; Rabe KG; Bamlet WR; Mer G; Sicotte H; Zhang C; Li H; Petersen GM; Fernandez-Zapico ME
J Biol Chem; 2021; 296():100634. PubMed ID: 33823155
[TBL] [Abstract][Full Text] [Related]
79. The expression of p16(INK4a), the product of a tumor suppressor gene for melanoma, is upregulated in human melanocytes by UVB irradiation.
Piepkorn M
J Am Acad Dermatol; 2000 May; 42(5 Pt 1):741-5. PubMed ID: 10775848
[TBL] [Abstract][Full Text] [Related]
80. A novel CDKN2A variant (p16
Li C; Liu T; Liu B; Hernandez R; Facelli JC; Grossman D
Pigment Cell Melanoma Res; 2019 Sep; 32(5):734-738. PubMed ID: 31001908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
